Trio Health Appoints Dr. Mia Nease as Chief Commercial Officer

Our Bureau

Trio Health (Trio), a leading clinical data solution provider, has announced the appointment of Mia Nease as its Chief Commercial Officer (CCO). In this role, Nease will lead the advancement of Trio’s commercialization strategy and oversee the development of innovative solutions to meet the evolving needs of Trio’s life sciences clients and collaborators.

Mia brings more than 25 years of experience commercializing scientific innovation to Trio. Her career path includes launching a division of Dell Computer in Asia Pacific, initiating a Life Science software strategy for Hewlett Packard, and helping PwC accelerate advisory consulting revenue in the healthcare and life sciences sectors. Most recently, Mia served as the Vice President of Partnerships for Komodo Health.

In addition to her full-time roles, Mia has served on advisory boards of three health-tech startups seeking revenue growth and strategic partnerships. While in her role as CCO at Trio, Mia will continue to serve on the board of Bryleos, an emerging biotechnology company.

Widely recognized as a pioneer in the healthcare technology and life sciences spaces, Mia will play a pivotal role in Trio’s continued expansion that includes the licensing of high-quality clinical data and unique offerings that support all phases of the biopharmaceutical product lifecycle. Mia’s commercial experience and vast international technology and life sciences network will usher in a new phase for Trio.

“There is enormous opportunity for Trio Health that lies ahead,” said Trio CEO, Brent Clough. “We are delighted to have found a high-caliber leader in Mia to accelerate our company to its next stage of growth and to help our customers achieve commercial success.”

“I have known Trio’s CEO Brent Clough for nearly a decade. Trio Health’s growth, combined with the leadership of Yoori Lee, President, reflects the evolution of the healthcare sector. I am honored to join Trio and to continue to grow their vision,” said Nease.

Author

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity

Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, today announced the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of Obesity and Type 2 Diabetes, with the potential to improve human Longevity. The World Health Organization estimates 650 million obese and 537 […]

Subscribe Now